SCHEMBL25435698

SCHEMBL25435698

Fc1cc(Cl)ccc1-c1c(F)c(F)c(F)c(F)c1F

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMO O15229 2/20 0.40
EGLN2 Q96KS0 1/20 0.39
S100A4 P26447 1/20 0.38
GRM2 Q14416 4/20 0.38
PTGS2 P35354 1/20 0.38
HSD11B1 P28845 1/20 0.36
FASN P49327 1/20 0.35
PDK2 Q15119 1/20 0.35
PDE4A P27815 2/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PPOX P50336 1/20 0.34
AHR P35869 1/20 0.34
CYP2C9 P11712 1/20 0.34
IDO1 P14902 1/20 0.33
BCHE P06276 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31118393 1.00 KMO (0.40) KMOEGLN2S100A4GRM2PTGS2
SCHEMBL8974517 0.86 KMO (0.42) KMOEGLN2S100A4GRM2PTGS2
SCHEMBL30688105 0.85 KMO (0.37) KMOEGLN2S100A4GRM2PTGS2
SCHEMBL25432867 0.85 KMO (0.37) KMOEGLN2S100A4GRM2PTGS2
SCHEMBL30598347 0.83 S100A4 (0.46) KMOEGLN2S100A4GRM2HSD11B1
SCHEMBL23638850 0.83 S100A4 (0.46) KMOEGLN2S100A4GRM2HSD11B1
SCHEMBL17514808 0.80 KMO (0.39) KMOEGLN2S100A4GRM2PTGS2
SCHEMBL27075579 0.79 CA1 (0.42) PTGS2
SCHEMBL25432559 0.78 KMO (0.38) KMOEGLN2S100A4GRM2HSD11B1
SCHEMBL17514897 0.77 KMO (0.37) KMOEGLN2S100A4GRM2PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260068883-A1 PROTOPORPHYRINOGEN OXIDASE INHIBITORS ENKO CHEM, INC. (US) 2026-03-12 US disclosed
US-12302900-B2 Protoporphyrinogen oxidase inhibitors ENKO CHEM, INC. (US) 2025-05-20 US disclosed
EP-4463000-A2 PROTOPORPHYRINOGEN OXIDASE INHIBITORS Enko Chem, Inc. (US) 2024-11-20 EP disclosed
WO-2024192147-A2 PROTOPORPHYRINOGEN OXIDASE INHIBITORS ENKO CHEM, INC. (US) 2024-09-19 WO disclosed
CN-118525002-A Protoporphyrinogen oxidase inhibitors 恩科化学公司 2024-08-20 CN disclosed
US-20240130365-A1 PROTOPORPHYRINOGEN OXIDASE INHIBITORS ENKO CHEM, INC. (US) 2024-04-25 US disclosed
US-11889833-B2 Protoporphyrinogen oxidase inhibitors ENKO CHEM, INC. (US) 2024-02-06 US disclosed
US-20230354809-A1 PROTOPORPHYRINOGEN OXIDASE INHIBITORS ENKO CHEM, INC. (US) 2023-11-09 US disclosed
US-20230354809-A1 PROTOPORPHYRINOGEN OXIDASE INHIBITORS ENKO CHEM, INC. (US) 2023-11-09 US disclosed
US-20230354809-A1 PROTOPORPHYRINOGEN OXIDASE INHIBITORS ENKO CHEM, INC. (US) 2023-11-09 US disclosed
WO-2023137309-A2 PROTOPORPHYRINOGEN OXIDASE INHIBITORS ENKO CHEM, INC. (US) 2023-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11889833-B2 Protoporphyrinogen oxidase inhibitors PPOX, PNPO, PPIF KMO 152/4885EGLN2 695/4885S100A4 2879/4885
US-20240130365-A1 PROTOPORPHYRINOGEN OXIDASE INHIBITORS PPOX, PNPO, PPIF KMO 152/4885EGLN2 695/4885S100A4 2879/4885
US-12302900-B2 Protoporphyrinogen oxidase inhibitors PPOX, PNPO, PPIF KMO 152/4885EGLN2 695/4885S100A4 2879/4885
US-20260068883-A1 PROTOPORPHYRINOGEN OXIDASE INHIBITORS PPOX, CYC1, CBR3 KMO 263/4885EGLN2 731/4885S100A4 3258/4885
US-20230354809-A1 PROTOPORPHYRINOGEN OXIDASE INHIBITORS PPOX, PNPO, PPIF KMO 152/4885EGLN2 695/4885S100A4 2879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.